Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cellectis S.A. - American Depositary Shares (NQ:CLLS)

2.880 +0.090 (+3.23%)
Streaming Delayed Price Updated: 10:31 AM EDT, Jun 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cellectis S.A. - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Cellectis Presents ‘Smart CAR T’ Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB)
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Provides Business Updates and Financial Results for Third Quarter 2024
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer
From Cellectis Inc.
Via GlobeNewswire
News headline image
CLLS Stock Earnings: Cellectis Beats EPS, Beats Revenue for Q2 2024 ↗
CLLS stock results show that Cellectis beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Cellectis Provides Financial Results for the Second Quarter 2024
From Cellectis Inc.
Via GlobeNewswire
News headline image
FDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL Treatment
From Cellectis Inc.
Via GlobeNewswire
News headline image
FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024
From Cellectis Inc.
Via GlobeNewswire
News headline image
CLLS Stock Earnings: Cellectis Beats EPS, Beats Revenue for Q1 2024 ↗
CLLS stock results show that Cellectis beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Cellectis Reports Financial Results for First Quarter 2024
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024
From Cellectis Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Appoints Arthur Stril as Interim Chief Financial Officer
From Cellectis Inc.
Via GlobeNewswire
News headline image
CLLS Stock Earnings: Cellectis Misses EPS, Misses Revenue for Q4 2023 ↗
CLLS stock results show that Cellectis missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)
From Cellectis Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.